Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If we are well passed the 5 day window...but we are still trading...then there is something about the allowed extension you mention, that is not apparent.
And again, IF we are trading Pink Limited, how would reporting requirements pertain here?
I see no sign of surrender by management. Quite the contrary, it looks like their focus remains on a successful recall of their loaned shares, for the full benefit of shareholders, for the entire amount of our OS, with no 40% carve out for a business combination. But I do think we will merge with Baudax, and quickly regain Nasdaq listing compliance with this merger.
The irony is beyond toleration of this search by the government to find a therapeutic that they already have, to alleviate public health and medical infrastructure concerns, that they themselves are allowing by negligently ignoring lenzilumab's authorization application.
"Then there's BA.2.86, which has been nicknamed Pirola and has more mutations than any of the other variants currently circulating — more than 30 — and has already been detected at least twice in the United States. But despite what experts call high outbreak potential, it's not the variant currently driving the current surge. Nonetheless, SARS-CoV-2, the virus that causes COVID, does one thing really well and that's mutate to evade our immune defenses. What the fall will look like in terms of COVID cases is yet to be seen, but things are not looking good as hospitalizations, infections and deaths are all on the rise. The latest vaccine updates can't get here soon enough — if people even decide to take them."
https://www.yahoo.com/news/covid-19-variants-driving-surge-222302021.html
Dear government, The $1.4B in awards that Humanigen shareholders/taxpayers are helping to pay for new covid therapies and vaccines, could be used to restore our Market Cap to where it was before the FDA granted themselves the power to "Decline" to make decisions on covid products, such as our lenzilumab, and the government could have the variant-agnostic lenz cocktail vaccine, and the therapeutic, that you will never find anywhere else but with Humanigen. Azzholes.
"US govt awards $1.4 billion for development of new COVID therapies, vaccines
Reuters
Tue, August 22, 2023"
Nothing mentioned about Humanigen
https://www.yahoo.com/news/us-govt-awards-1-4-194306288.html
"...the new BA.2.86 lineage of coronavirus may be more capable than older variants in causing infection in people who have previously had COVID-19 or who have received vaccines."
This is exactly what Geert Vanden Bossche predicted would happen, and he expressed his concern specifically as this could impact twice-infected patients.
It looks like the embedded newscast was filmed last month, before a vote in Brevard County in regards to mainly mRNA vaccines.
Here are excerpts of the Resolution they voted upon, and a few other Florida counties also voted upon. I'm glad it is noted that both covid, and mRNA covid vaccines, are viewed as bioweapons.
https://www.theflstandard.com/brevard-county-gop-declares-covid-vaccines-bioweapons-calls-for-legal-action/
We already see news, now, about how covid vaccines are required for some college admittance. And FOX news is scoffing at measures such as mask wearing.
Perhaps surprisingly, I don't agree with the commentary from FOX news. What containment measures worked, or didn't work, as well as what vaccines and therapeutics worked, or didn't work, are irrelevant to a new variant, especially if it is a manufactured variant, at least in part.
The variant agnostic lenzilumab IS REQUIRED to treat covid pneumonia, and to maintain the innate immune response, against these variants. And I will look forward to seeing the lenz cocktail used as a preventative, as well.
I think a lot of people open up one of my posts, and see so much written, that they just go on to the next post. That's why I started doing 'ZoomLenz,' in which I try to get the main subject of my recent postings down to a single bullet point.
But I did write a two sentence post in which I used more sentence clauses in the second sentence than I have probably ever used.
"I really hope that our 10-Q will focus on the positive news that I think WE CAN CONTROL. That is, a review of our stellar CMML results, prompting the initiation of a related aGvHD trial, which could lead to a cure for certain myelodysplastic leukemias, with announcement of a share recall of our Outstanding Shares, which I think we own entirely, and the declaration of a 5:1 forward stock split, in preparation of an intended merger, resulting in the re-listing of our stock on the Nasdaq Stock Exchange."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172586987
I actually liked that post. But I wish I would have mentioned a possible CAR-T development, because I think there will be one. I should have also mentioned that I think we could end up with authorization or an approval for covid, and the effect it has on our innate immune response system. Maybe we'll see something in that regard from the study of lenz on Long Covid. And although Pfizer at least got their bone marrow cancer treatment authorized, which was more than Gilead could do, there is no way that hospital administrators aren't going to look at lenz as a much more attractive therapeutic.
I think management has placed Humanigen at the strongest defensive point possible, where positive news will take our share price farther and faster than if we were still on Nasdaq. There may be more flattening, than loading, but we'll certainly welcome new buyers, who will be jumping on the train. It could only be nicer if our lenz cocktail was ready to be revealed, and lenz was shown to prevent not only cancers, such as CMML, but covid, as well. But, the new buyers we pick up on our short squeeze will have something to look forward to, along with us.
LOL, your pessimism is overstated, or our volume wouldn't be so low. I will only allow you "scepticism," at best, and only briefly (just kidding). With our recent trial data, including the near pathway of a cure for CMML, and an EUA for covid, sitting on the 10-Q has no justification, other than to make the forced covering caused by a recall of our loaned shares as painful as possible.
I echo DTGoody's sentiment, that we will file the 10-Q, which I think is completed, except for a possible update.
That update, in my opinion, will include news that we will merge with Baudax, and avoid a business combination with them (not factor in a 40% sacrifice of our OS).
To me, this is all about announcing:
a positive regulatory update,
and, a recall of our loaned shares, in the worst possible environment for brokerages who have a short exposure of 110M shares that they will have to buy, in a much less liquid market.
I think we may have been downgraded from Pink Current to Pink Limited.
"Pink Market Tiers: Current and Limited
Within the Pink market exist tiers. Companies that fully abide by the disclosure rules are dubbed "current," whereas those who do the bare minimum under Rule 15c2-11 and are perhaps late with filings are downgraded to the “Pink Limited” market tier.
Pink Limited is essentially a demotion from the Pink current status for those who don't fully abide by Rule 15c2-11. That demotion can lead to restrictions and is generally less favorable.
When a company no longer meets the requirements for limited information, it will be moved to the Expert Market, where there are no public broker-dealer quotations."
https://www.investopedia.com/terms/p/pinksheets.asp
I entered a small sell order to see how that possible demotion affected trading, and it appeared to have no affect at all.
But it seems that a brokerage with significant short exposure could have hell in the event of a recall of loaned shares.
This is beyond my pay grade. It's a whole new chapter in the playbook for me to witness.
Thanks, DTG. So I assume that yield sign has been up since we filed the NT 10-Q.
Thanks for the link, Yooo. I got a yield sign to show up on the quote box. But I'm expecting to see that loaned shares are being recalled. I don't know what to think. Nothing shows up on my Schwab platform regarding a yield
Seriously, no kidding.
I don't see anything, sosjtb.
Is Gilead's CEO O'Day really worth the 11% bump in compensation he got, up to $21.6M?
I think Humanigen would have loved to have lenz as the treatment therapeutic in their bone marrow cancer trial. We just didn't want to give them exclusive use of lenz. So they go out and buy 'Forty Seven, Inc' for $4.9B, and now the FDA has placed the trial on clinical hold.
Meanwhile, Pfizer's bone marrow cancer treatment is targeting a $4B market for their product. And lenz sits idly by, awaiting FDA approval, for years. What a wasted opportunity for Gilead, and for Humanigen, both of whom are in Black Rock's portfolio.
More news on magrolimab.
"US FDA puts Gilead Sciences blood cancer drug studies on hold
Reuters
August 21, 2023
Gilead Sciences (GILD.O) said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.
The company gained access to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.
The company said the U.S. Food and Drug Administration (FDA) had paused screening and enrollment of new study participants, while the patients already under the studies may continue to receive treatment."
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-gilead-sciences-blood-cancer-drug-studies-hold-2023-08-21/
Baudax files 8-K this morning. Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
"The Purchase Agreement contains customary representations and warranties and agreements of the Company and the Purchasers and customary indemnification rights and obligations of the parties. The Company is expected to receive net proceeds of approximately $1.6 million in connection with the Offering, after deducting advisory fees and related offering expenses. The Company intends to use the net proceeds from the Offering for pipeline development activities and general corporate purposes. The closing of the Offering and the Concurrent Private Placement is expected to occur on or about August 21, 2023, subject to satisfaction of customary closing conditions.
The Shares, Series E Pre-Funded Warrants, and the shares of Common Stock issuable upon exercise of the Series E Pre-Funded Warrants in the Offering were offered by the Company pursuant to a registration statement on Form S-3 (File No. 333-253117)..."
https://www.sec.gov/Archives/edgar/data/1780097/000119312523216610/d540795ddefa14a.htm
"
"And by the way, Baudax filed a second prospectus today."
Two different file numbers are reflected in the Registration statements. One is an S-1 filing, the other is an S-3 filing.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523093995/d497372ds1.htm
https://www.sec.gov/Archives/edgar/data/1780097/000119312521043475/d46186ds3.htm
"Form S-1 – long form typically used for IPOs and sometimes for other primary and secondary sales of securities. Form S-3 – short form typically used for follow-on offerings and public resales of a company's securities by selling shareholders, and available only if eligibility requirements are met."
https://www.google.com/search?q=what+is+the+diference+between+an+S-1+and+an+S-3%3F&sca_esv=558339750&ei=g2jgZOj2Nb2wqtsPyMiwiAE&ved=0ahUKEwioxJmWk-iAAxU9mGoFHUgkDBEQ4dUDCBA&uact=5&oq=what+is+the+diference+between+an+S-1+and+an+S-3%3F&gs_lp=Egxnd3Mtd2l6LXNlcnAiMHdoYXQgaXMgdGhlIGRpZmVyZW5jZSBiZXR3ZWVuIGFuIFMtMSBhbmQgYW4gUy0zPzIFEAAYogRI8ExQhwhY2ShwAXgBkAEAmAGXAaAB-AGqAQMxLjG4AQPIAQD4AQHCAgoQABhHGNYEGLAD4gMEGAAgQeIDBRIBMSBAiAYBkAYI&sclient=gws-wiz-serp
Thank you for that info, eb.
And by the way, Baudax filed a second prospectus today.
Speaking of covid and changes in our innate immune response system:
"Friday, August 18, 2023
Severe COVID-19 may lead to long-term innate immune system changes
NIH-funded research links alterations to inflammatory protein, underscores vaccine importance...
In these experiments, some of the subjects received antibodies at the early stage of illness that prevented IL-6 from binding to cells. During recovery, these mice and people had lower levels of altered stem cell gene-expression instructions, monocyte production and inflammatory cytokine production than subjects that didn’t receive the antibody. In addition, the lungs and brains of mice that received the antibodies had fewer monocyte-derived cells and less organ damage."
I wonder which antibodies, administered early, that prevented IL-6 from binding to cells, they used. In any event, this small study seems to be based on, and validates, the lenzilumab method of action.
https://www.nih.gov/news-events/news-releases/severe-covid-19-may-lead-long-term-innate-immune-system-changes
Added again. This coming Monday was our deadline to regain Nasdaq compliance. I doubt that going to the OTC was conditional, but you never know. Besides, I think we'll qualify for Nasdaq again if we complete our business combination with Baudax.
FYI, Baudax released a prospectus.
https://www.sec.gov/Archives/edgar/data/1780097/000119312523214745/d516691d424b3.htm
I can't see a situation in which you would ever have to apologize to me for anything, even though I try to express myself more precisely in some instances, because of your counsel, but fail on times to do so.
I yield and agree to your point that lenz doesn't prevent or treat covid infection. I have been saying "covid pneumonia" every time I can remember to do so, and that is always in deference to your guidance.
So, I would like to see the reinfection rate of covid pneumonia in lenz treated patients.
Forgive me in advance if I forget to add "pneumonia" in discussing this. But it's going to be harder to do so in the future, because lenz is being touted as part of a cure in CMML cancer, because that cancer is myeloid-driven, and, although lenz doesn't treat that cancer, it prevents it by blocking the virus from attaching to GM-CSF.
Restoring the body's immune response is an element of discussion I have seen in regards to the use of lenz. I think keeping the integrity of our immune response is critical, as these manufactured covid variants have the intention of changing our bodies' natural responses. I think we'll learn more about this as we continue to develop our lenz/vaccine/anti-viral cocktail, as well as we incorporate TeraImmune's TReg development.
Besides all else, I want to have, and express, the fullest appreciation of lenzilumab's potential. Management is not positioned to speculate. They can only state facts that are proven, in my opinion. So there's no way anything I say is going to be 100% accurate. And I'm glad to see that you recognize that.
Always, always, appreciate hearing from you, eb.
I got focused on your deficient immune numbers on my initial response to your post, and did not address the short squeeze you mentioned that we longs are hoping for.
My interest in this company was because I knew from the short squeeze the company had previously, that government agencies were abusing their discretionary authority here. While that is almost always fatal to the victimized company, there are a very few company managers who know how to capitalize on regulatory complacency. We have such managers. I saw that when I read the filing that described their share structure.
The short squeeze is imminent. An article written about our first short squeeze noted that a key takeaway was, "Fundamentals are not important in a short squeeze situation."
https://www.reddit.com/r/GME/comments/lo5pvo/this_is_what_a_short_squeeze_looks_like_come_and/?rdt=57254
The heavy lifting has already been done. Management has already bought back every share they have issued, and they are ready to recall their loaned shares, which will force shorts to cover because they sold the borrowed shares. I'm as sure of this as I can be.
Thanks, eb. The subject of lenzilumab restoring the immune response system is developing in our trial data. I think it is hugely important, and will become even more so.
But, the covid re-infection rate in lenz patients is also something I have long thought is hugely important, and I don't see any data on that yet, after all this time.
I'm looking forward to learning more on both subjects. I'd even like to have the raw data to be able to make those determinations, if it is not something that is being analyzed.
I'm scheduled for a procedure in the doctor's office in the morning, either an angioplasty or a stent into the artery near my left hip, to remove a plaque build-up. I could be home by noon. Nothing says "get well soon" like a short squeeze. Did I get that right? Maybe it's a quick hug, but I'm pretty sure I'd get better faster with a short squeeze.
Maybe it was even before the LIVE-AIR trial commenced, and all we had to go by were studies, but I knew that lenz could have helped my wife. Management knew that lenz would be effective when used with remdesivir and dexamethasone. None of that mattered, and my wife's condition deteriorated.
No, it is not my job to be Inspector Clouseau. But it's my self-appointed job to support the effort to get this drug to other patients, like my wife was.
Worthless doctors don't bring a cancer cure to market, nor even a potential covid cure.
Black Horse took an 8.24% stake in Baudax for 500K shares, at about $0.69 per share.
https://money.cnn.com/quote/shareholders/shareholders.html?symb=bxrx&subView=institutional
From what I see, at this point, Humanigen stands ready to execute the merger with Baudax.
I study what I see, and draw conclusions, Yooo. I'm trying to understand what is going on, and share my opinions. There is more to this situation with Baudax to be learned.
I don't see anything relevant to us in the Baudax 10-Q and 8-K filed today.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000095017023042918/bxrx-20230630.htm
https://www.sec.gov/ix?doc=/Archives/edgar/data/1780097/000119312523213881/d523400d8k.htm
We'll have to see if we get any hint from Humanigen. Was this strictly a Black Horse, et al, transaction?
I was hoping this issue was going to be simple enough for me to understand, but it isn't.
https://www.sec.gov/Archives/edgar/data/1178179/000101359423000580/baudax13ga1-07102023.htm
Okay. I kind of agree with you. I think our stock price is going to catch on fire.
And thank you, too, because you caused me to discover that Pusan has been renamed Busan, which I didn't know. My first wife and I adopted a 3 month old Korean girl who came from Pusan in the 1980's.
My second wife came from Laos, and we had 2 daughters together, one of whom mainly lives with me still.
Makes me hope that we get an approval from S. Korea. They conducted a safety trial for lenz, and I hope we get an Asia-Pacific approval not only in Australia, but in S. Korea and the Philippines, too.
The SEC's website is where you'll be able to find Q2 earnings, which are running a little late right now.
https://www.sec.gov/cgi-bin/browse-edgar?company=humanigen&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
Yes, hopefully it is the accomplishment of one of the things we can control, outside of a regulatory authorization or approval.
"I really hope that our 10-Q will focus on the positive news that I think WE CAN CONTROL. That is, a review of our stellar CMML results, prompting the initiation of a related aGvHD trial, which could lead to a cure for certain myelodysplastic leukemias, with announcement of a share recall of our Outstanding Shares, which I think we own entirely, and the declaration of a 5:1 forward stock split, in preparation of an intended merger, resulting in the re-listing of our stock on the Nasdaq Stock Exchange."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172586987
If this is followed-up with the announcement of the recall of our loaned shares, then the fuse on this rocket will be lit!!!
Thanks, eb. I actually hope that management of both Humanigen and Baudax kept the Nasdaq Appeals Panel apprised of this merger/business combination, and that Nasdaq is expecting this move, with the aim of both companies re-gaining compliance with Nasdaq listing standards in this way, either jointly or separately. We actually had until the 21st to accomplish this, if Nasdaq was amenable to the ruse of our voluntary delisting.
Well, isn't this a coincidence? LOL!
The company who I think is our intended merger partner or business combination partner, also filed an NT 10-Q today.
Baudax expects that their 10-Q "...will be filed on or before the fifth calendar day following the prescribed due date..."
https://www.sec.gov/Archives/edgar/data/1780097/000119312523212960/d519256dnt10q.htm
Humanigen Short Interest
"Short Borrow Fee Rates
Start, Min, Max, Latest (Borrow Rates)
2023-08-15 44.39 44.39 66.13 66.13"
https://fintel.io/ss/us/hgen
Thanks for the continuing updates, Chaplain. I found one of your postings yesterday as a good resource for vaccine-related issues. And there is the notice we were informed of by management that an uptick in ICU utilization may cause one of our partners to add lenz to a platform study. Necessity will be the mother of our success, especially as the US wants to use mRNA based variant-specific vaccine formulations.
Humanigen being a legitimate company, with progress being made, potential for more success, and value in our R&D, does distinguish us from similarly-situated companies.
But the threat we face is very real. Big Pharma needs to fight for their revenue dollars, and they fully leverage their influence over regulatory agencies to deny our authorization, and preclude government stockpiling of lenzilumab.
Half a dozen, or so, of my highlighted posts I shared on Twitter, mention the recall of our loaned shares. That would not be possible unless management was able to accumulate shares without that being detected. Hence, the design of our share structure. But when the loaned shares are recalled, it will show the market management's conviction of faith in the company, and that, in itself will entice buying. Of course, the real buying pressure will come from short sellers having to buy the shares they borrowed and sold short. Spoiler alert, there just won't be enough shares, which is why I added sell orders at $150 and $250, to go along with my existing sell orders at $100 and $200, with three sell orders below $100.
Our previous short squeeze was the result of just a share recall, with no regulatory approvals as an added buying incentive. But I think Dale and Durrant are trying to secure either a CMML or covid approval.
But you are right to be cautious, as am I, and as we all should be. This cabal of Big Pharma influence over a captured regulatory system is very powerful. I'm hoping we get an approval from Australia, and maybe even the UK.
ZoomLenz 3 of 3. Focus on currently highlighted Twitter posts.
>First patient dosed in the aGvHD trial indicates forward progress being made, and this could complement the results seen in the CMML trial, which may prove to be a cure for this type of cancer.
>The patented lenz/vaccine/anti-viral cocktail could address the ominous prognosis for twice re-infected covid patients that virologists such as Geert Vanden Bossche fear for the next wave of infections.
>people who are just taking a position will gain the most...Regulatory news, such as TGA approval, announced with a share recall. etc., could result in a significant short squeeze
>I think a share recall will be announced, and then a 5:1 forward stock split will be declared. A bear trap.
>Our previous experience in this situation relied on a recall of our loaned shares
>CMML safety and efficacy data, with ACTIV-5 safety and efficacy data from late-stage patients, could provide enough information for an EUA
>discretionary authority be stripped from all government agencies
>The FDA is charged with approving or denying authorizations for drugs. They granted themselves the power to "Decline" to make decisions on covid products, such as lenzilumab.
>The 8-K doesn't reflect the value of all the shares owned by the company, nor the explosive price appreciation of the shares once the company recalls those shares, forcing shorts to cover.
>Any media focus on Shkreli will be nothing more than click bait, focused on the entirely irrelevant
>what little buzz there has otherwise been has largely been related to CAR-T
>the company would not agree to Gilead's exclusive use of lenz...necessity is what will force our success.
>Shareholders and management should not be deprived of the profit we deserve because the FDA granted themselves the authority to Decline to make decisions on approvals of small-cap products that pose a financial threat to their Big Pharma sponsors.
>Sen Rand Paul files criminal referral regarding Fauci about gain-of-function research emails
>I really hope that our 10-Q will focus on the positive news that I think WE CAN CONTROL. That is, a review of our stellar CMML results, prompting the initiation of a related aGvHD trial, which could lead to a cure for certain myelodysplastic leukemias, with announcement of a share recall of our Outstanding Shares, which I think we own entirely, and the declaration of a 5:1 forward stock split, in preparation of an intended merger, resulting in the re-listing of our stock on the Nasdaq Stock Exchange.
>No management team should have to figure out a way for their company to survive when it's product is clinically proven superior in safety and efficacy to any other product, but does not get regulatory approval to treat patients, let alone save their lives.
>I maintain what I have been saying for quite some time, that the company owns every share they have issued. Evidence of that was demonstrated by the float changing to a level that is 110M shares higher than the currently stated OS of 119,080,135 shares.
>We are likely to submit to MHRA for a covid approval in the UK. And we may also have renewed incentive for BARDA and CRADA to support the authorization of lenz to fulfill DOD requirements.
>Why give up 40% of the company if we have repurchased every share we have issued, and we have some regulatory news that would empower us to recall our loaned shares, and probably cause the biggest short squeeze in history?
>the "control" I mentioned was gained exactly where Durrant told us it would likely come from, in Australia with our partner SAHMRI